Bausch Health Companies (NYSE:BHC) Trading Down 6.7% on Insider Selling

Bausch Health Companies Inc (NYSE:BHC) fell 6.7% on Wednesday following insider selling activity. The stock traded as low as $21.08 and last traded at $21.16, 3,156,665 shares were traded during trading. A decline of 20% from the average session volume of 3,924,546 shares. The stock had previously closed at $22.69.

Specifically, EVP Christina Ackermann sold 3,418 shares of Bausch Health Companies stock in a transaction on Monday, August 12th. The shares were sold at an average price of $22.45, for a total value of $76,734.10. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 11.87% of the company’s stock.

Several brokerages have commented on BHC. Mizuho set a $45.00 target price on shares of Bausch Health Companies and gave the stock a “buy” rating in a research report on Thursday, June 20th. Zacks Investment Research upgraded shares of Bausch Health Companies from a “hold” rating to a “buy” rating and set a $27.00 target price on the stock in a research report on Tuesday, May 21st. ValuEngine upgraded shares of Bausch Health Companies from a “strong sell” rating to a “sell” rating in a research report on Monday, July 29th. Piper Jaffray Companies set a $29.00 target price on shares of Bausch Health Companies and gave the stock a “buy” rating in a research report on Tuesday, June 11th. Finally, Cantor Fitzgerald set a $32.00 target price on shares of Bausch Health Companies and gave the stock a “buy” rating in a research report on Friday, May 31st. Three research analysts have rated the stock with a sell rating, three have issued a hold rating and twelve have given a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $29.68.

The company has a market capitalization of $7.85 billion, a PE ratio of 5.19, a price-to-earnings-growth ratio of 0.26 and a beta of 0.76. The firm’s 50-day simple moving average is $23.79 and its 200 day simple moving average is $23.91. The company has a debt-to-equity ratio of 8.94, a quick ratio of 0.92 and a current ratio of 1.21.

Bausch Health Companies (NYSE:BHC) last released its quarterly earnings data on Tuesday, August 6th. The company reported $1.03 EPS for the quarter, missing the consensus estimate of $1.06 by ($0.03). Bausch Health Companies had a positive return on equity of 52.12% and a negative net margin of 10.88%. The business had revenue of $2.15 billion during the quarter, compared to analysts’ expectations of $2.15 billion. During the same quarter in the prior year, the firm earned $0.93 earnings per share. Bausch Health Companies’s quarterly revenue was up 1.1% on a year-over-year basis. As a group, equities analysts anticipate that Bausch Health Companies Inc will post 4.24 earnings per share for the current year.

Several institutional investors have recently added to or reduced their stakes in the stock. FIL Ltd boosted its position in shares of Bausch Health Companies by 69.6% in the 1st quarter. FIL Ltd now owns 10,545,300 shares of the company’s stock worth $260,170,000 after buying an additional 4,327,851 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Bausch Health Companies by 4.0% in the 2nd quarter. Vanguard Group Inc. now owns 9,513,863 shares of the company’s stock worth $239,940,000 after buying an additional 363,579 shares in the last quarter. Bank of Montreal Can boosted its position in shares of Bausch Health Companies by 43.7% in the 2nd quarter. Bank of Montreal Can now owns 5,318,505 shares of the company’s stock worth $134,133,000 after buying an additional 1,616,428 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Bausch Health Companies by 9.8% in the 2nd quarter. Renaissance Technologies LLC now owns 3,037,200 shares of the company’s stock worth $76,598,000 after buying an additional 272,000 shares in the last quarter. Finally, Clearbridge Investments LLC boosted its position in shares of Bausch Health Companies by 0.5% in the 1st quarter. Clearbridge Investments LLC now owns 2,897,282 shares of the company’s stock worth $71,563,000 after buying an additional 14,610 shares in the last quarter. Institutional investors and hedge funds own 53.70% of the company’s stock.

Bausch Health Companies Company Profile (NYSE:BHC)

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.

Featured Article: What is a Stop Order?

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply